On the basis of our data, we conclude that overexpression of Trx-1 in DLBCL cell lines and primary cells is associated with growth and survival, as well as chemoresistance, and that targeting Trx-1 with the novel Trx-1 inhibitor PX-12 may reverse chemoresistance. The gene discussed is TXN; the disease is diffuse large B-cell lymphoma.